Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era
Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era
Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences.
The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy.
At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.
Author: Melinda E. Cooper
Publisher: University of Washington Press
Published: 02/20/2008
Pages: 208
Binding Type: Paperback
Weight: 0.82lbs
Size: 8.83h x 7.01w x 0.59d
ISBN: 9780295987910
Review Citation(s):
Scitech Book News 06/01/2008 pg. 179
About the Author
Melinda Cooper is a research fellow with the Centre for Biomedicine and Society, Kings College London.